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Hospitalizations Associated with Pneumococcal Infection within the  
Medicare Population Among Vaccinated and Non-vaccinated Patients 
 
Silky F. Webb, Pharm.D. 
ABSTRACT 
Background: Streptococcus pneumoniae is the primary causative agent of pneumonia in older 
adults.  Vaccination is the only tool to protect against pneumococcal infection; however, 
vaccination rates remain far below the Healthy People 2010 objective of 90% coverage.  The 
number one reason for such low rates is attributed to controversy over the protective efficacy of 
the vaccine in preventing nonbacteremic pneumonia (eg, community-acquired pneumonia [CAP]).      
Objectives: The primary objectives of this study were to assess the incidence of pneumonia, 
pneumonia requiring hospitalization, and pneumonia hospitalization costs.  
Methods: In this retrospective cohort study of Medicare beneficiaries aged 65 years in 2003, 
subjects were selected based on exposure status.  Exposure was defined as receipt of the 23-
valent pneumococcal polysaccharide vaccine (PPV23).  Vaccinated persons were then matched 
1:1 on gender and the presence of any comorbidity to unvaccinated persons.  Subjects were 
followed up for 1 year (January 1, 2004 through December 31, 2004). The primary outcomes 
were pneumonia, pneumonia requiring hospitalization, and hospitalization costs.  Mantel-
Haenszel chi-square or logit was used to estimate the relative risk (RR) associated with 
vaccination and each outcome and Proc Ttest was used to test the difference between mean 
hospital costs of the vaccinated and non-vaccinated.  
Results: During the follow-up period, 443 patients were diagnosed with pneumonia; 266 had 
previously been vaccinated and 177 had no documented receipt of prior vaccination.  Results of 
the Chi-square analysis revealed a significant association between vaccination and the risk of 
pneumonia, as the vaccinated were 50% more likely to develop pneumonia than were the non-
vaccinated (Adjusted RR: 1.50; 95% CI: 1.25, 1.81).  Approximately 67% of patients diagnosed 
with pneumonia required hospitalization; of which, 183 were previously vaccinated and 115 had 
v 
no documented receipt of prior vaccination.   There was no association between vaccination and 
risk of pneumonia requiring hospitalization (P value 0.4001).  However, the vaccine was 
associated with a significant reduction in hospital costs (P value 0.004).           
Conclusions: The results of this study suggest that use of the vaccine may be associated with 
cost savings due to a reduction in hospitalization.  
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CHAPTER ONE 
Introduction 
Pneumococcal infection is a major source of morbidity and mortality in older adults over 
age 65 years (Loeb, 2003).  The primary causative agent of pneumococcal infection is 
Streptococcus pneumoniae (CDC, 2006; Kupronis et al, 2003; Loeb, 2003).    Upon colonizing the 
respiratory tract, S. pneumoniae can cause disseminated invasive infections, including 
bacteremia/septicemia and meningitis; pneumonia and other lower respiratory tract infections; 
and upper respiratory tract infections, including otitis media and sinusitis (DHHS, 1997).  In 
adults, 60% to 80% of pneumococcal bacteremia is associated with pneumonia (DHHS, 1997).  
Adults older than 65 years are at a particularly higher risk for S. pneumoniae colonization due to 
their advanced age, frequent presence of chronic illnesses, and institutionalism (ie, residence 
within a long term care facility [LTCF]).  In the United States (U.S.) and Canada, it is estimated 
that between 5,000 and 30,000 cases of pneumococcal infection per annum occur in elderly 
patients (Butler et al, 1999).  Case-fatality rates in this population range from 30% to 40% (CDC, 
2006; Kupronis et al, 2003).     
Nonbacteremic pneumonia, the most common manifestation of pneumococcal infection 
among the elderly (Jackson et al, 2003), exerts a great burden on the individual and society (De 
Graeve et al, 2004).  Hospitalization due to nonbacteremic community-acquired pneumonia 
(CAP) in the U.S. has been estimated to range from $7,000 to $8,000 per admission or $4 million 
per 100,000 population, accounting for approximately 90% of the total cost to treat nonbacteremic 
CAP (De Graeve et al, 2004).   
There are currently two 23-valent pneumococcal polysaccharide vaccines in the U.S.; 
manufactured by Merck and Company, Inc. (Pneumovax
®
 23) and Lederle Laboratories (Pnu-
Immune
®
 23).  In late 1983, the reformulated 23-valent vaccine replaced the 14-valent vaccine.  
The 23 serotypes represented in the vaccine cause 85% of all invasive infections (DHHS, 1997).  
The pneumococcal vaccine is recommended for those individuals at high risk for infection; this 
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includes individuals older than 65 years, residents of LTCFs, and individuals with multiple 
comorbidities and chronic conditions (DHHS, 1997).  Unlike the influenza vaccine which is 
recommended yearly, the pneumococcal vaccine has been recommended as a once in a lifetime 
injection.  Revaccination is recommended for those persons aged 65 years who received their 
primary vaccination ≥5 years previously (DHHS, 1997).   
One of the national Healthy People 2010 objectives is to achieve 90% pneumococcal 
vaccination coverage among residents of LTCFs and older adults greater than 65 years (DHHS, 
2000).  Based upon the latest estimates from the Centers for Disease Control and Prevention 
(CDC), vaccination rates remain far below this goal as only 49.9% of those aged 65 to 74 years 
and 60.9% of those 75 years and older report ever being vaccinated (CDC, 2001b).  One reason 
for low immunization rates may be continued controversy over the clinical efficacy of the vaccine 
in this population (Butler et al, 1993).  
Problem Statement  
  Previous studies on the cost-effective of the pneumococcal polysaccharide vaccine in 
people 65 years and older in the U.S. have been positive (Sisk et al, 1986; Sisk et al, 1997).   The 
results of these studies are limited as the efficacy of the vaccine in the prevention of pneumonia 
is assumed to be equivalent to the efficacy of the vaccine in the prevention of invasive disease 
(Sisk et al, 1986).  Despite this major flaw and controversy over the protective efficacy of the 
vaccine in the prevention of nonbacteremic pneumonia, the Advisory Committee on Immunization 
Practices (ACIP) has considered lowering the universal vaccination age from 65 years to 50 
years (Sisk et al, 2003).    Inconclusive results on the clinical efficacy of the vaccine in the 
prevention of nonbacteremia pneumonia warrant additional studies (Simberkoff et al, 1993). 
Research Objectives and Hypotheses 
In an attempt to understand why such low rates of pneumococcal immunization exist 
among the older adults, we must gain an understanding of the patient and provider factors that 
surround the administration of the vaccine.  In addition, until we gain more consistent results, 
more studies are warranted on the efficacy of the vaccine against nonbacteremic pneumococcal 
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infections in individuals 65 years and older.  The primary objectives of this study were to assess 
the incidence of pneumonia, incidence of pneumonia requiring hospitalization, and pneumonia 
hospitalization costs among vaccinated and non-vaccinated Medicare beneficiaries.  As a 
secondary objective, we will describe the demographic characteristics of and circumstances 
surrounding the administration of the pneumococcal polysaccharide vaccine.  Our research 
objective and major hypotheses are summarized in Table 1. 
 
Table 1. Research Objectives: Questions and Hypotheses 
Primary Research Objectives 
Questions & Null Hypotheses (Ho) 
#1. To assess the incidence of pneumonia in vaccinated and non-vaccinated patients  
Ho: There is no difference in the incidence of pneumonia in those that are vaccinated versus 
those that are not vaccinated 
#2. To assess the incidence of pneumonia  requiring hospitalization in vaccinated and 
non-vaccinated patients 
Ho: There is no difference in hospitalization rates among patients that are vaccinated versus 
those that are not vaccinated 
#3. To assess the hospitalization costs among the vaccinated and non-vaccinated 
Ho: There is no difference in hospitalization costs among patients that are vaccinated versus 
those that are not vaccinated 
 
In the next section, we will highlight the findings of studies conducted among the elderly, 
those aged at least 55 years.  Because the incidence of S. pneumoniae strains vary around the 
world, our review was restricted to studies conducted in the U.S. elderly population.  Additionally, 
because the 14-valent vaccine was replaced by the 23-valent vaccine in late 1983, we also 
restricted the review to include only those studies evaluating the protective efficacy of the 23-
valent vaccine.   
Literature Review 
A Pubmed search was conducted for 1983 to January 2007 using “pneumococcal”, 
“vaccine”, “randomized”, “efficacy”, “effectiveness”, “cohort studies”, “case-control studies”, 
“resource utilization” and combinations of these and other Boolean search terms.  So that 
relevant studies on older adults would not be omitted, search restrictions did not include age.  
The bibliography of a meta-analysis (Dear et al, 2006) of previous pneumococcal vaccine trials 
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was also used to identify additional studies.  Using the methods described, numerous studies 
were identified.  Studies that did not include the 23-valent pneumococcal polysaccharide vaccine 
(PPV23) were excluded.    
As a result, a total of eight observational studies were identified and are summarized in 
the Appendix.  Of the studies identified, there was one indirect cohort study (Butler et al, 1993); 
two retrospective cohort studies (Jackson et al, 2003; Fisman et al, 2001); one nested case-
control study (CDC, 2001c); three matched case-control studies (Sims et al, 1988; Shapiro et al, 
1991; Farr et al, 1995); and one population-based case series (Chi et al, 2006).  All but four 
observational studies exclusively addressed the protective efficacy of the vaccine in older adults 
aged 55 years or older (Fisman et al, 2006; Butler et al, 1993; Shapiro et al, 1991; Forrester et al, 
1987).  Despite enrolling children aged 2 years and greater, Shapiro et al (1991), and Butler et al 
(1993) estimated vaccine efficacy for subgroups that included immunocompetent patients aged 
65 to 74 years and immunocompetent patients 65 years and older, respectively.  In general, 
across all of the case-control studies cases, cases were identified as people with positive cultures 
(CDC, 2001c; Farr et al, 1995; Shapiro et al, 1991; Sims et al, 1988).  The indirect cohort study 
conducted by Jackson et al (2003) drew from the population of a managed care organization 
(Group Health Cooperative; Washington State).  Chi et al (2006) drew from the same study 
population to conduct a population-based case-series.  The indirect cohort study conducted by 
Butler et al (1993) analyzed national surveillance data for pneumococcal infections submitted to 
the CDC by U.S. hospital laboratories.  The 23-valent vaccine was used exclusively in four trials 
(Sims et al, 1988; Shapiro et al, 1991; Butler et al, 1993; Farr et al, 1995).  In another four trials, 
patients were adminstered either the 14-valent vaccine (PPV14) or PPV23 (CDC, 2001c; Jackson 
et al, 2003; Fisman et al, 2006; Chi et al, 2006).   
Shapiro et al (1991) conducted a hospital-based case-control study.  From 1984 to 1990, 
patients from 11 hospitals with laboratory-confirmed pneumococcal infection and an indication for 
pneumococcal vaccine were enrolled as cases.  Cases and controls were matched 1:1 on age, 
underlying illness, and site of hospitalization.  The protective efficacy of the vaccine in the overall 
population was 56% (95% confidence interval [CI]: 42%, 67%).  The vaccine was only 21% (95% 
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CI: -55%, 60%) effective in the immunocompromised patients; the protective efficacy in this 
subgroup was significantly less than that in the immunocompetent subgroup which included 
adults aged 55 years and older (1-OR: 61%; 95% CI: 47%, 72%).  When stratified by increasing 
age, the protective efficacy of the vaccine was only statistically significant for those aged 55 to 74 
years.  Based on these data, the authors concluded that there may be some benefit in 
vaccinating the elderly, even at the extremes of ages (Shapiro et al, 1991).        
Sims et al (1988) conducted a multicenter, case-control study of hospitalized older adults 
55 years of age and older with pneumococcal bacteremia, meningitis, or any other 
bacteriologically confirmed pneumococcal infection during a 5-year period.  Patients were 
excluded from the study if there was evidence of immunosuppression due to disease or iatrogenic 
disease.  A total of 366 patients were included in the study; their mean age was 69.5 ± 9.5 years.  
After logistic regression modeling to control for confounding variables, the vaccine efficacy was 
calculated to be 70% (95% CI: 37%, 86%).  The authors of this study concluded that the vaccine 
confers substantial protection from serious pneumococcal infections in immunocompetent elderly 
(Sims et al, 1988).  Another case-control study conducted by Farr et al (1995) demonstrated an 
81% (95% CI: 34%, 94%) protective efficacy.  The mean age of cases and controls in this study 
were 52.8 ± 2.0 years and 57.7 ± 1.5 years, respectively.  In an attempt to ensure that cases and 
controls were equally likely to have a prior exposure to pneumococcal vaccine, the logistic 
regression model matched on eight variables.  To date no other case-controls has ever matched 
on this number of variables.  The results of this study further support the conclusions drawn by 
previous studies (Farr et al, 1995).   
In a nested case-control study conducted in 2001 among residents of a nursing home in 
New Jersey (USA), the risk factors for pneumococcal pneumonia were evaluated (CDC, 2001c).  
Cases included nine residents hospitalized with pneumonia.  Controls were matched to cases in a 
2:1 ratio and randomly selected from among nursing home residents without pneumonia 
symptoms residing in the same wing where most of the case-patients had resided from March 1, 
2001 through April 26, 2001.  Median age of the cases and controls was similar; 86 years and 85 
years, respectively.  Pneumonia was strongly associated with failure to be vaccinated as zero of 9 
14 
case-patients developed disease versus 9 of 18 controls (odds ratio [OR]: 0; 95% CI: 0.0, 0.7) 
(CDC, 2001c).  This study further underscores the importance of pneumococcal vaccination in the 
elderly. 
Jackson et al (2003) conducted a retrospective cohort study of elderly members of a 
staff-model managed care organization, Group Health Cooperative (GHC), over a 3-year period.  
The primary outcomes were hospitalization due to community-acquired pneumonia (validated by 
chart review), pneumonia treated in the outpatient setting (determined from administrative data 
sources), and pneumococcal bacteremia.  Using multivariate Cox proportional-hazard models to 
control for age, sex, nursing-home residence or nonresidence, smoking status, medical 
conditions, and receipt or nonreceipt of influenza vaccine, the authors evaluated the association 
between pneumococcal vaccination and risk of each outcome.  Receipt of the pneumococcal 
vaccine was associated with a significant reduction of pneumococcal bacteremia (hazard ratio 
[HR]: 0.56; 95% CI: 0.33, 0.93) but a slightly increased risk of hospitalization for pneumonia (HR: 
1.14; 95% CI: 1.02, 1.28).  On the other hand, receipt of pneumococcal vaccination did not alter 
the risk of outpatient pneumonia (HR: 1.04; 95% CI: 0.96, 1.13) or any cause of community-
acquired pneumonia, whether or not it required hospitalization (HR: 1.07; 95% CI: 0.99, 1.14).  In 
another retrospective cohort study conducted by Fisman et al (2006), hospitalized vaccine 
recipients with community-acquired pneumonia were less likely to die of any cause than were 
individuals with no record of vaccination (OR: 0.50; 95% CI: 0.43, 0.59).   In comparison to 
nonvaccination, vaccination was also noted to lower the risk of respiratory failure (adjusted OR: 
0.67; 95% CI: 0.59, 0.76) and other complications and reduced median length of stay by 2 days 
(P value <0.001) (Fisman et al, 2006).  Based on the results of these studies, pneumococcal 
vaccine is effective in preventing bacteremic pneumonia; however other strategies are needed to 
prevent nonbacteremic pneumonia (Fisman et al, 2006; Jackson et al, 2003).   
Investigators of the CDC conducted an indirect cohort study to test their hypothesis that 
pneumococcal infections occurring in vaccinated individuals should be fess frequently due to 
vaccine serotypes than infections occurring in unvaccinated controls (Butler et al, 1993).  Patients 
aged 2 years or more who were of known vaccination status and vaccination date, who had onset 
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of illness between May 1978 and April 1992 but greater than 30 days from vaccination until onset 
of illness, and from whom a vial isolate from blood or cerebrospinal fluid (CSF) was received and 
serotyped were included in the study.  For immunocompetent adults older than 65 years, the 
study demonstrated a vaccine efficacy of 70% (95% CI: 57%, 85%).  The authors of this study 
concluded that pneumococcal polysaccharide vaccine effectively prevents invasive disease due 
to pneumococcal serotypes included in the vaccine in several patient populations for whom the 
vaccine is currently recommended.  They also concluded that the vaccine may provide a shorter 
period of protection as well as less protective efficacy among patients immunocompromised by 
certain underlying illnesses, including older age (Butler et al, 1993).    
Chi et al (2006) conducted a population-based case series of community-dwelling adults 
aged 65 years and older.  Patients with at least 2 years of enrollment in GHC and a diagnosis of 
pneumococcal bacteremia (confirmed by a positive blood culture or chart review) between 1988 
and 2002 were included in the study.  A total of 200 elderly patients were identified; on average 
they had aged 78 years and 61% were female.  Prior to the onset of bacteremia, 40% of patients 
had chart-documented receipt of pneumococcal vaccination.  Approximately 10% of the study 
population was treated on an outpatient basis; of the remainder that was hospitalized (90%), 16% 
were admitted to an intensive care unit (ICU).  Of the survivors, 43% were discharged to a higher 
level of care.  After using a logistic regression model to control for age, sex, and pneumococcal 
vaccination status, predictors of death included coronary artery disease (OR: 4.6; 95% CI: 1.4, 
14.5) and immunocompromising conditions (OR: 5.0; 95% CI: 1.6, 15.7).  Based on the results of 
this study, there was no difference in the outcomes (ie, survival, hospital length of stay, and 
discharge to a higher level of care) of patients who did and did not receive pneumococcal 
vaccination (Chi et al, 2006).     
Pneumococcal vaccination rates among the elderly range from 49.9% among those aged 
65 to 74 years to 60.9% among those aged 75 years and older (CDC, 2001b).  Controversy over 
the clinical efficacy of the pneumococcal polysaccharide vaccine has been hypothesized as the 
number one reason for such low vaccination rates Butler et al, 1993; Fedson et al, 1994; 
Hirschmann et al, 1994).  The most common manifestation of pneumococcal infection among the 
16 
elderly is nonbacteremic pneumonia (Jackson et al, 2003).  In patients with nonbacteremic 
pneumonia the vaccine failed to confer protection (Jackson et al, 2003) but was associated with a 
reduction in hospital LOS and death due to any cause (Fisman et al, 2006).  The protective 
efficacy of the vaccine in preventing invasive pneumococcal infection (ie, bacteremia, meningitis, 
and infection of other normally sterile fluids) in U.S. elderly adults ranges from 61% to 75% (Sims 
et al, 1988; Shapiro et al, 1991; Butler et al, 1993).  In U.S. elderly patients with pneumococcal 
bacteremia, there was no difference in outcomes (ie, all-cause mortality, hospitalization, and 
hospital LOS) between those who did and did not receive the vaccine (Chi et al, 2006).          
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CHAPTER TWO 
Methods  
 In this retrospective cohort study, Medicare beneficiaries 65 years of age were assessed 
over a 2-year period, January 2003 through December 2004 (Figure 2).  By nature of the study 
design, patients were selected based on their exposure status.  Exposure was defined as receipt 
of the 23-valent pneumococcal polysaccharide vaccine, PPV23, (identified by Current Procedural 
Terminology [CPT] code 90736).   
 
Figure 1. Study Design 
 
 
Medicare beneficiaries with evidence of PPV23 administration during the enrollment period (July 
1, 2003 through December 31, 2003) were matched to individuals with no documented receipt of 
PPV23 based on gender and the presence of any comorbidity.  Only those aged 65 years of age 
in 2003 were included in the analysis to reduce the risk that the comparison group had been 
vaccinated prior to the enrollment period.  Any comorbidity was defined as those conditions 
associated with high risk for the development of pneumococcal infection as defined by ACIP 
(Table 2).  The study protocol was approved by the investigational review boards of the Centers 
for Medicare and Medicaid Services (CMS) and the University of South Florida and is in 
compliance with Health Insurance Portability and Accountability Act (HIPAA) regulations. 
 
 
 
Study Period 
01/01/2003 12/31/2003 
Enrollment Period 
07/01/2003 12/31/2003 
Follow Up Period 
(1 Year) 
Pre Period 
(0.5 Years) 
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Table 2. ACIP PPV Recommendations 
Comorbid Conditions of Interest: ICD-9 Codes 
Alcoholism: 303.1-303.3, 303.9 
Asplenia: 759.0 
Cerebrospinal Leak: V45.2 
Diabetes Mellitus (DM): 250, 250.0-250.9 
Chronic Pulmonary Disease 
Emphysema, Bronchitis, Asthma: 490-496 
Pneumocomycoses due to external agent: 500-505 
Chronic Liver Disease 
Cirrhosis: 571.0-571.3, 571.5-571.6, 571.8, 571.9 
Chronic Hepatitis: 571.4, 571.40, 571.41, 571.49 
Human Immunodeficiency Virus (HIV): V07-V09, 042, 079.51-079.53 
Immune Deficiency: 279.0, 279.00-279.06, 279.09, 279.1, 279.10-279.13, 279.19, 279.2, 279.3 
Cardiovascular 
Heart Disease: 420-429, 429.0-429.3, 429.8, 429.9 
Myocardial Infarction: 410, 412 
CHF: 428, 425, 402.01, 402.11, 402.91 
Cerebrovascular Disease: 434, 435, 436, 437, 438 
Key: ACIP – Advisory Committee on Immunization Practices 
 
Data Source  
 The data source for this study was the Medicare 5% beneficiary encrypted files (BEF) for 
the most recent two-year period from 2003 to 2004; available from CMS.  The BEF represents a 
random 5% sample of the entire Medicare population which essentially includes all U.S. residents 
age 65 and older as well younger age groups who may qualify for Medicare due to a diagnosis of 
end stage renal disease (ESRD) or certain disabilities.  The BEF data includes Durable Medical 
Equipment (DME), Inpatient Facility, Hospice, Outpatient Facility, Home Health Agency (HHA), 
Skilled Nursing Facility (SNF), and Physician / Supplier (Part B) claims.  This analysis is 
conducted using claims from the Inpatient Facility, Outpatient Facility, and Physician / Supplier 
files.  
Study Population 
 Beneficiaries enrolled in Medicare Parts A and B between January 1, 2003 and 
December 31, 2004 were included in the study.  The current milestone for interventions to 
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prevent disease or to screen for asymptomatic disease is age 65 years.  As such, in an attempt to 
assure no prior receipt of the pneumococcal vaccine, the study was further limited to patients who 
were age 65 years in 2003.  Beneficiaries aged less than or greater than 65 years were excluded 
from the study.  
Outcomes 
 The primary outcome was pneumonia, identified on the basis of International 
Classification of Diseases, Ninth Revision; Clinical Modification (ICD-9 CM) codes (480 throught 
486).  The incidence rate of pneumonia was calculated as the number of new patients diagnosed 
with pneumonia divided by total person-years of follow-up for all patients at risk for developing 
pneumonia.  The total number of patients at risk for developing pneumonia totaled 7,388 and they 
were followed up for 1 year; as such, there were 7,388 persons-years of follow-up for patients at 
risk for developing pneumonia.  Pneumonia requiring hospitalization was also evaluated.  The 
incidence rate of hospitalization due to pneumonia was calculated as the number of new patients 
with pneumonia requiring hospitalization (i.e., denoted as an inpatient visit in our claims data) 
divided by total person-years of follow-up for patients with pneumonia.  From January 1, 2004 
through December 31, 2004, a total of 443 patients were diagnosed with pneumonia; thus, there 
were 433 person-years of follow-up for persons at risk for pneumonia requiring hospitalization.  
Beneficiaries were followed up for a total of 1 year; thus, there were a total of 7,388 patient-years 
of follow-up.  As a secondary objective, we also evaluated pneumonia hospitalization costs.  
Mean costs were derived as the total claim payment amount for each claim of beneficiaries with 
an inpatient claim for pneumonia divided by the total number of patients with an inpatient visit for 
pneumonia.    
Statistical Analysis 
 Descriptive statistics such as mean, standard deviation (SD), frequency, and percentage 
were generated for demographic characteristics, comorbid conditions, and vaccine utilization 
patterns.  The frequency of categorical variables was compared using Chi-squared (א
2
) or 
Fisher’s exact test.  Mantel-Haenszel chi-square or logit was used to estimate the relative risk 
(RR) associated with vaccine exposure and outcome (ie, pneumonia and hospitalizations due to 
20 
pneumonia).  Means were compared using Proc Ttest for equal variance.  The alpha level for 
declaring statistical significance was P value <0.05.  Data were analyzed using Statistical 
Analysis Software (Version 9.1, SAS Institute, Inc., Cary, North Carolina).    
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CHAPTER THREE 
Baseline Characteristics 
 The cohort consisted of 7,388 persons who were followed up for 1 year (7,388 person-
years), 3,694 (50%) received the pneumococcal vaccine during the enrollment period (July 1, 
2003 through December 31, 2003).  A majority (55.1%) was female, the most common 
documented race was Caucasian, and nearly 50% of all patients had one or more predisposing 
comorbidity (Table 4).  The most common comorbidities, occurring in ≥10% of patients, were 
cardiovascular disease and chronic pulmonary disease.  Less than 1% of the vaccinated and 
unvaccinated resided in a LTCF.   
 
Table 3. Baseline Characteristics 
Characteristic Vaccinated 
(N=3,694) 
Non-vaccinated 
(N=3,694) 
P value 
Gender, n (%) 
Female 
Male 
 
2,035 (50.0) 
1,659 (50.0) 
 
2,035 (50.0) 
1,659 (50.0) 
 
1.000 
Race, n (%) 
African American 
Caucasian 
Hispanic 
Other 
 
192 (5.2) 
3,407 (92.2) 
17 (0.46) 
270 (2.12) 
 
369 (9.99) 
3,147 (85.2) 
36 (0.97) 
142 (3.84) 
 
<0.001 
Comorbidities, n (%) 
Any Comorbidity 
Alcoholism 
Asplenia 
Cardiovascular 
Cerebrovascular 
Cerebrospinal Leak 
Chronic Liver Disease 
Chronic Pulmonary Disease 
HIV 
Immune Deficiency 
 
1,704 (46.3) 
7 (0.19) 
1 (0.03) 
768 (20.8) 
170 (4.60) 
0 (0.00) 
44 (1.19) 
637 (17.2) 
1 (0.03) 
5 (0.14) 
 
1,704 (46.1) 
30 (0.81) 
0 (0.00) 
611 (16.5) 
157 (4.25) 
0 (0.00) 
43 (1.16) 
527 (14.3) 
1 (0.03) 
1 (0.03) 
 
1.000 
<0.001 
0.500 
<0.001 
0.462 
N/A 
0.914 
<0.004 
0.500 
0.094 
Resides in LTCF, n (%) 
No 
Yes 
 
3,681 (99.7) 
13 (0.35) 
 
3,678 (99.6) 
16 (0.43) 
 
0.577 
Key: N/A – not applicable 
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Of the 3,694 patients with documented receipt of the vaccine, a majority (78.28%) was 
vaccinated during a physician office visit to a non-institutional provider.  Of the remainder, 0.28% 
(n=103) of patients were vaccinated while at a hospital outpatient department, rural health clinic, 
renal dialysis facility, outpatient rehabilitation facility, comprehensive outpatient rehabilitation 
facility, community mental health center, or ambulatory surgical center.  The remaining 21.52% 
(n=795) were vaccinated at some other healthcare facility.  The most common provider specialty 
administering the vaccine was Internal Medicine (33.96%) followed by Family Practice (31.51%) 
and a Public Health or Welfare Agency (11.50%).  Table 4 outlines the specialty distribution for 
providers administering the vaccine. 
Table 4. Provider Specialty Distribution 
Specialty Frequency Percent 
Internal Medicine 1,332 33.96% 
Family Practice 1,236 31.51% 
Public Health or Welfare Agency 451 11.50% 
Pulmonary Disease 107 2.73% 
Other 357 9.13% 
 
The recommended frequency for pneumococcal vaccination is once in a lifetime; unless 
however 5 years lapse between when a patient is vaccinated for the first time and their 65
th
 
birthday (DHHS, 1997).  Despite these recommendations, a total of 181 patients (4.9%) were 
revaccinated within 1 year of their primary vaccination. 
Outcomes 
Pneumonia Disease Incidence 
 A total of 443 patients were assigned an ICD-9-CM code for pneumonia (codes 480 
through 486); of which, 266 patients were previously vaccinated and 177 had no documented 
receipt of prior vaccination.  This equates to an incidence rate of 36.0 per 1,000 person-years for 
the vaccinated and 24.0 per 1,000 person-years for the non-vaccinated.  Results of the Chi-
square analysis revealed a significant association between vaccination and the risk of pneumonia 
(P value <0.0001).  The vaccinated were 50% more likely to develop pneumonia than were the 
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non-vaccinated (Adjusted RR: 1.50; 95% CI: 1.25, 1.81).   The results of this analysis are 
summarized in Table 5.                   
Pneumonia Requiring Hospitalization 
 Of the 443 patients diagnosed with pneumonia, approximately 67.2% (n=298) required 
treatment within the hospital setting.  Of the patients with pneumonia requiring hospitalization, 
183 were previously vaccinated and 115 had no documented receipt of prior vaccination.  The 
incidence of pneumonia requiring hospitalization in the vaccinated was almost 2.0-times that of 
the unvaccinated (41.3 per 100 person-years versus 26.0 per 100 person-years).  Results of the 
Chi-square analysis failed to reveal a significant association between vaccination and pneumonia 
requiring hospitalization (P value 0.401).  The results of this analysis are summarized in Table 5.    
 
Table 5. Incidence and Risk of Pneumonia and Pneumonia Requiring Hospitalization in 
Relation to Vaccination Status 
 Pneumonia (ICD-9-CM codes 480 – 486) 
Variable Disease Hospitalization 
Adjusted rate* 
     Vaccinated 
     Non-vaccinated 
Per 1,000 person-years 
36.0 
24.0 
Per 100 person-years 
24.8 
15.6 
Mantel-Haenszel relative risk (95% CI) 
     P value 
1.50 (1.25, 1.81) 
<0.001 
1.06 (0.93, 1.21) 
0.401 
*Risk ratios were adjusted for sex and the presence of any comorbidity. 
Pneumonia Hospitalization Costs 
Among this study population of vaccinated (n=183) and non-vaccinated (n=115) 
Medicare beneficiaries aged 65 years, the vaccine was associated with significant reduction in 
mean hospital costs (P value 0.004). Hospitalization due to pneumonia ranged from $2,361 to 
$3,553 per admission for vaccinated patients and from $3,479 to $5,663 per admission for non-
vaccinated patients and from; the average cost per admission for the vaccinated and non-
vaccinated was $2,957 and $5,663, respectively.  Because claim payment amounts for the non-
vaccinated ranged from $0 to $90,419, we re-ran the analysis excluding those persons with claim 
payment amounts of $0 (n=16, non-vaccinated persons).  As a result, the minimum claim 
payment amount for the non-vaccinated changed from $0 to $16 and the mean cost per hospital 
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admission for the non-vaccinated increased by $343 to $6,006. The results of this analysis 
remained significant (P value 0.001) and are summarized in Table 6. 
 
Table 6. Pneumonia Hospitalization Costs in Relation to Vaccination Status   
 Pneumonia Hospitalization Costs 
Vaccination Status Mean (95% CI) Range P value 
All Persons Hospitalized for Pneumonia 
Vaccinated (n=183) $2,957 ($2,307, $3,553) $6 - $31,046 
Non-vaccinated (n=115) $5,663 ($3,479, $7,846) $0 - $90,419 
0.004 
Minus Persons with Claim Payment Amounts = $0 
Vaccinated (n=183) $2,957 ($2,307, $3,553) $6 - $31,046 
Non-vaccinated (n=99) $6,006 (3$,705 - $8,306)  $16 - $90, 419 
0.001 
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CHAPTER FOUR 
Discussion  
 In this retrospective cohort study of 7,388 Medicare beneficiaries aged 65 years, 
vaccinated persons were 50% more likely to develop pneumonia than were non-vaccinated 
persons (P value <0.001).  Despite controlling for the presence of any comorbidity, it is possible 
that residual confounding influenced our estimates of association between vaccination and risk of 
pneumonia.  These results are not surprising as the vaccinated group was comprised of more 
immunocompromised patients than the non-vaccinated group; 21% versus 17%, respectively, for 
cardiovascular disease and 17% versus 14%, respectively, for chronic pulmonary disease (P 
value <0.001 for both comorbidities).  Similar to other studies, we assume that S. pneumoniae 
was a common cause of pneumonia in this population (Jackson et al, 2003).  Based on this 
assumption and our presumption of residual confounding, we can not conclude from these results 
that vaccination is not effective in preventing pneumococcal pneumonia. The direction of the 
association between vaccination and risk of pneumonia for this study (Adjusted RR: 1.50; 95% 
CI: 1.25, 1.81) is similar to the direction of the association between vaccination and outpatient 
pneumonia (Adjusted HR: 1.04; 95% CI: 0.96, 1.13) found in the retrospective cohort study 
conducted by Jackson et al (2003).  Despite having 98% power to detect a 15% change in the 
risk of outpatient pneumonia and vaccination, Jackson and colleagues failed to detect such a 
decrease in risk (Jackson et al, 2003).     
 The results of our second analysis are consistent with the population based-case series 
study conducted by Chi et al  (2006), which concluded that there was no evidence that the 
vaccine is associated with a reduction in the risk of hospitalization (Chi et al, 2006).  In a 
retrospective cohort study conducted by Jackson et al (2003), the vaccine was associated a 
significant increase in risk of hospitalization for CAP; the vaccinated were 14% more like to be 
hospitalized for CAP than were the non-vaccinated (Adjusted HR: 1.14: 95% CI: 1.02, 1.28) 
(Jackson et al, 2006).  In the same study, the vaccinated were found to be 6% more likely to be 
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discharged from the hospital with a diagnosis of pneumonia than were the non-vaccinated; 
however, the results of this analysis did not reach statistical significance (Adjusted HR: 1.06; 95% 
CI: 0.98, 1.16) (Jackson et al, 2006).  Despite there being no difference in the rate of pneumonia 
requiring hospitalization among the vaccinated versus the non-vaccinated, our study suggests 
that there is a difference in hospital costs.   
 To date, no other study has looked at pneumonia hospitalization costs among vaccinated 
and non-vaccinated Medicare beneficiaries.  On average, hospital admission costs for the 
vaccinated Medicare beneficiaries with pneumonia were $2,705 less than hospital admission 
costs for non-vaccinated beneficiaries (P value 0.004).  Claim payment amounts ranged from $0 
to $90,219 for the non-vaccinated and from $6 to $31,046 for the vaccinated; the upper limit of 
the claim payment amount range for the non-vaccinated was nearly three-times that of the 
vaccinated.  This difference in magnitude may be due to the presence of outliers or longer 
hospital stays.  Because we feel it is impossible to be hospitalized for pneumonia and not to incur 
costs, we re-ran our analysis excluding the 16 non-vaccinated persons with claim payment 
amounts of $0.  The vaccine was still associated with a significant reduction in hospital costs; the 
difference in mean costs increased from $2,705 to $3,049 (P value <0.001).   
 In an attempt to understand why such low rates of pneumococcal immunization exist 
among older adults, we investigated the circumstances surrounding the administration of the 
vaccine to identify the provider specialties most frequently administering the vaccine and to 
quantify the proportion of patients revaccinated within 1 year of primary vaccination.  Based on 
the results of our analysis, the most common provider specialties administering the vaccine was 
Internal Medicine (33.96%) and Family Practice (31.51%).  Because such a large percentage of 
patients suffer from comorbid conditions of the pulmonary and cardiovascular systems, 
pulmonary disease and cardiovascular disease specialists should be administering the vaccine at 
much higher rates than those observed in this study; only 2.63% of the patients in our study were 
administered the vaccine by a pulmonary disease specialist.    The ACIP recommended 
vaccination frequency for S. pneumoniae is once in a time lifetime; revaccination is recommended 
for those persons aged 65 years who received their primary vaccination ≥5 years previously.  In 
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our study, a total of 181 patients (4.9%) were revaccinated within 1 year of their primary 
vaccination.  Further investigation is warranted to distinguish true revaccination from duplicate 
claims.  We were not able to investigate this issue due to the limitations of our data.   
Limitations 
Much like other observational studies, this study is subject to the limitation of a 
nonrandomized study design (Jackson et al, 2003).  The primary source of these data was the 
CMS administrative claims database.  As such, ascertainment of medical conditions (ie, 
pneumonia and other chronic medical conditions) and/or procedures (ie, pneumococcal 
vaccination) is subject to some degree of misclassification as the claims data are only as good as 
the person entering claims for adjudication (Jackson et al, 2003).  Additionally, date variables in 
the CMS administrative claims database are formatted as 8 digit numeric variables denoting 
month, quarter, and year (ie, MMQQYYYY).  As such, we could not further investigate 
revaccination rates or the possibility of outliers among our claim payment amounts for the non-
vaccinated. 
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Appendix A: Studies of Pneumococcal Vaccine Effectiveness in Older Adults 
Reference /  
Study Dates 
Study Population  /  
Infection Type  
Study Design  /  
Vaccine Valence 
Key Primary /  
Secondary Endpoints 
Results 
Sims et al, 1988* 
 
Study Dates 
Not Reported 
Study Population 
• Hospitalized 
immunocompetent >55 
yrs 
 
Infection Type 
• Invasive Infection** 
Study Design 
• Case Control (N=366) 
 Cases, n=122 
 Controls, n=244 
 
Vaccine Valence 
• PPV14 or PPV23 
There was no 
distinction between 
primary and secondary 
endpoints 
 
• Invasive Infection** 
Invasive Infection 
OR: 0.30 
1- OR: 0.70 
95% CI: 0.37, 0.86 
 
Shapiro et al, 1991* 
 
Study Dates 
Not Report 
Study Population 
• Patients admitted to one 
of 11 participating 
hospitals in Connecticut, 
USA 
• Subgroup of Interest: 
Immunocompetent 65-74 
yrs  
 
Infection Type 
• Invasive Infection** 
Study Design 
• Case Control (N=2,108) 
 Cases, n=1,054 
 Controls, n=1,054 
 
Vaccine Valence 
• PPV14 or PPV23 
There was no 
distinction between 
primary and secondary 
endpoints 
 
• Vaccination Rates 
• Invasive Infection**  
Vaccination Rates 
Cases: 13%  
Controls: 20%  
P value <0.001 
 
Invasive Infection 
(Immunocompetent 65-74 yrs) 
OR: 0.39 
1 – OR: 0.61 
95% CI: 0.47, 0.72  
Butler et al, 1993 
 
Study Dates 
May 1978 – April 1992 
Study Population 
• Patients with 
pneumococcal 
bacteremia and/or 
meningitis at institutions 
participating in the 
national pneumococcal 
Study Design 
• Indirect cohort (N=2,827) 
 Unvaccinated, n=515 
 Vaccinated, n=2,322 
 
Vaccine Valence 
Primary 
• Bacteremia and/or 
Meningitis 
• Protection Duration 
Primary 
Bacteremia and/or Meningitis 
(Immunocompetent ≥65 yrs) 
OR: 0.25 
1- OR: 0.75 
95% CI: 0.57, 0.85 
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Reference /  
Study Dates 
Study Population  /  
Infection Type  
Study Design  /  
Vaccine Valence 
Key Primary /  
Secondary Endpoints 
Results 
surveillance program 
• Subgroup of Interest: 
Immunocompetent ≥65 
yrs 
 
Pneumococcal Infection 
Type 
• Bacteremia and/or 
Meningitis 
• PPV14 or PPV23  
Protection Duration 
(Overall Study Population)   
<2 yrs: 51% (22%, 69%) 
 2 – 4 yrs: 54% (28%, 70%) 
5 – 8 yrs: 71% (24%, 89%) 
≥9 yrs: 80% (16%, 95%) 
Farr et al, 1995 
 
Study Dates 
January 1, 1981 –  
December 31, 1987 
Study Population 
• Patients aged ≥2 yrs with 
pneumococcal 
bacteremia and chronic 
illness or those aged ≥65 
yrs 
 
Infection Type 
• Bacteremia 
Study Design 
• Case Control 
 Cases, n=85 
 Controls, n=152 
 
Vaccine Valence 
• PPV14 or PPV23 
Primary 
• Bacteremia 
Bacteremia 
(Overall Population) 
OR: 0.19 
1- OR: .81 
95% CI: 0.34, 0.94 
CDC, 2001c 
 
Study Dates 
April 3 – 24, 2001 
Study Population 
• Residents of a nursing 
home in New Jersey, 
USA 
 
Infection Type 
• Bacteremic Pneumonia 
Study Design 
• Nested Case Control 
(N=23) 
 Cases, n=9 
 Controls, n=18 
 
Vaccine Valence 
• PPV23 
There was no 
distinction between 
primary and secondary 
outcomes 
 
• Bacteremic 
Pneumonia  
Bacteremic Pneumonia 
OR: 0 
95% CI: 0.0, 0.7 
Jackson et al, 2003 
 
Study Dates 
Study Population 
• Members of Group 
Health Cooperative in 
Study Design 
• Retrospective Cohort 
(N=47,365) 
Primary 
• Hospitalization for 
CAP 
Primary 
Hospitalization for CAP  
(rate per 100,000 person yrs) 
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Reference /  
Study Dates 
Study Population  /  
Infection Type  
Study Design  /  
Vaccine Valence 
Key Primary /  
Secondary Endpoints 
Results 
March 1, 1998 –  
February 28, 2001 
Washington State ≥65 
yrs 
 
Pneumococcal Infection 
Type 
• CAP 
• Pneumococcal 
Bacteremia 
 Unvaccinated, n=21,052 
 Vaccinated, n=26,313 
 
Vaccine Valence 
• PPV23  
 
• Outpatient 
Pneumonia 
• Pneumococcal 
Bacteremia  
 
Secondary 
• Hospitalization with 
a Pneumonia 
Discharge Dx 
Unvaccinated: 10.4 
Vaccinated: 11.8 
Adjusted HR: 1.14 
95% CI: 1.02, 1.28 
Outpatient Pneumonia 
(rate per 100,000 person yrs) 
Unvaccinated: 23.2 
Vaccinated: 25.7 
Adjusted HR: 1.04 
95% CI: 0.96, 1.13 
 
Pneumococcal Bacteremia 
(rate per 100,000 person yrs) 
Unvaccinated: 0.68 
Vaccinated: 0.38 
Adjusted HR: 0.56 
95% CI: 0.33, 0.93 
 
Secondary 
Hospitalization with a 
Pneumonia Discharge Dx 
(rate per 100,000 person yrs) 
Unvaccinated: 18.8 
Vaccinated: 19.9 
Adjusted HR: 1.06 
95% CI: 0.98, 1.16 
 
All-cause Mortality 
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Reference /  
Study Dates 
Study Population  /  
Infection Type  
Study Design  /  
Vaccine Valence 
Key Primary /  
Secondary Endpoints 
Results 
(rate per 100,000 person yrs) 
Unvaccinated: 50.1 
Vaccinated: 42.0 
Adjusted HR: 0.96 
95% CI: 0.91, 1.01 
Fisman et al, 2006 
 
Study Dates 
September 1999 –  
December 2003 
Study Population 
• Adults hospitalized with 
CAP 
 
Infection Type 
• CAP 
Study Design 
• Population-Based Case 
Series (N=62,918) 
 
Vaccine Valence 
• PPV23 
There was no 
distinction between 
primary and secondary 
outcomes 
 
• All-cause mortality 
• Adverse Events 
(other than in-
hospital death) 
• Hospital LOS 
 
All-cause mortality 
(Overall Population) 
OR: 0.29 
95% CI: 0.26, 0.33 
 
Adverse Events (other than in-
hospital death), OR (95% CI) 
ARD: 0.67 (0.59, 0.76) 
Tracheostomy: 0.49 (0.33, 
0.73) 
Acute renal failure: 0.55 (0.46, 
0.65) 
Sepsis Syndrome: 0.74 (0.61, 
0.90) 
Cardiac Arrest: 0.55 (0.46, 
0.65) 
 
Hospital LOS 
Unvaccinated: 6.5 days 
Vaccinated: 4.5 days 
Unknown Status: 5.5 days 
P value <0.001 for pairwise 
comparisons by log rank test 
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Reference /  
Study Dates 
Study Population  /  
Infection Type  
Study Design  /  
Vaccine Valence 
Key Primary /  
Secondary Endpoints 
Results 
Chi et al, 2006 
 
Study Population 
1988 – 2002 
Study Population 
• Community-dwelling 
patients >65 yrs with at 
least 2 yrs enrollment in 
Group Health 
Cooperative 
 
Infection Type 
• Pneumococcal 
Bacteremia 
Study Design 
• Population-Based Case 
Series (N=200) 
Vaccine Valence 
• PPV23 
There was no 
distinction between 
primary and secondary 
outcomes 
• All-cause Mortality 
• Hospitalization 
• ICU Admission 
• Hospital LOS 
• Discharge to Home 
Care 
• Discharge to Nursing 
Home 
All-cause Mortality 
Unvaccinated: 10.0% 
Vaccinated: 11.3% 
P value 0.78 
 
Hospitalization 
Unvaccinated: 90.0%  
Vaccinated: 88.8% 
P Value 0.78 
 
Hospital LOS 
Unvaccinated: 7.4 days  
Vaccinated: 5.7 days 
P Value 0.11 
 
Discharge to Home Care 
Unvaccinated: 25.0%  
Vaccinated: 19.7% 
P Value 0.24 
 
Discharge to Nursing Home 
Unvaccinated: 19.4%  
Vaccinated: 19.7% 
P Value 0.24 
Key: ARD – acute respiratory distress, CAP – community-acquired pneumonia, CI – confidence interval, Dx – diagnosis, HR – hazard ratio, ICU – intensive care unit, LOS – length of 
stay, PPV – pneumococcal polysaccharide vaccine, OR – odds ratio, yrs – years, USA – United States of America 
*Summarized from abstract as full manuscript was not available due to the date published.  
**Invasive infection was defined as a diagnosis of pneumococcal pneumonia, meningitis, or any other bacteriologically confirmed pneumococcal infection. 
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Appendix B: Abbreviations 
ACIP – Advisory Committee on Immunization Practices 
ARD – acute respiratory distress 
BEF – beneficiary encrypted files 
CAP – community-acquired pneumonia 
CDC – Centers for Disease Control and Prevention 
CI – confidence interval 
CMS – Centers for Medicare and Medicaid Services 
CPT - Current Procedural Terminology 
DME – durable medical equipment 
Dx - diagnosis 
ESRD – end stage renal disease 
HHA – Home Health Agency 
HR – hazard ratio 
ICD-9-CM - International Classification of Diseases, Ninth Revision; Clinical Modification 
ICU – intensive care unit 
LOS – length of stay 
LTCF – long term care facility 
OR – odd ratio 
PPV14 – 14-valent pneumococcal polysaccharide vaccine 
PPV23 – 23-valent pneumococcal polysaccharide vaccine 
SNF – skilled nursing facility 
yrs – years 
U.S. – United States 
USA – United States of America 
